Search

Displaying results 6191 - 6200 of 9324 in total
  1. Drug

    Labuxtinib

    go.drugbank.com/drugs/DB21658
    Experimental

    The usage of the INN stem '-tinib' in the name indicates that Labuxtinib is a tyrosine kinase inhibitor. Labuxtinib has a monoisotopic molecular weight of 377.13 Da.

  2. Drug

    Talorasib

    go.drugbank.com/drugs/DB21686
    Experimental

    The usage of the INN stem '-rasib' in the name indicates that Talorasib is a Ras protein inhibitor. Talorasib has a monoisotopic molecular weight of 604.24 Da.

  3. Drug

    Girocitinib

    go.drugbank.com/drugs/DB21692
    Experimental

    The usage of the INN stem '-citinib' in the name indicates that Girocitinib is a Janus kinase inhibitor. Girocitinib has a monoisotopic molecular weight of 326.14 Da.

  4. Drug

    Nedemelteon

    go.drugbank.com/drugs/DB21700
    Experimental

    The usage of the INN stem '-melteon' in the name indicates that Nedemelteon is a melatonin receptor agonist. Nedemelteon has a monoisotopic molecular weight of 258.14 Da.

  5. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  6. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. … It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.

  7. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter … It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661]

  8. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  9. Drug

    Carafiban

    go.drugbank.com/drugs/DB19813
    Experimental

    The usage of the INN stem '-fiban' in the name indicates that Carafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  10. Drug

    Licostinel

    go.drugbank.com/drugs/DB19864
    Experimental

    The usage of the INN stem '-stinel' in the name indicates that Licostinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. Licostinel has a monoisotopic molecular weight of 274.95 Da.